SCHEMBL6108535

SCHEMBL6108535

CC(NC(=O)c1ccc(N)cc1)N(C)C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.53
NPC1 O15118 1/20 0.53
LMNA P02545 3/20 0.47
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
POLB P06746 1/20 0.47
PKM P14618 1/20 0.47
APEX1 P27695 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
SMN1; SMN2 Q16637 4/20 0.46
ALDH1A1 P00352 3/20 0.44
SLC22A2 O15244 1/20 0.44
SLC22A1 O15245 1/20 0.44
TSHR P16473 1/20 0.44
ACHE P22303 1/20 0.44
MAPK1 P28482 1/20 0.44
CYP2C19 P33261 1/20 0.44
MAPT P10636 2/20 0.43
KDM4E B2RXH2 1/20 0.43
HIF1A Q16665 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL853579 0.81 MLYCD (0.59) RAB9ANPC1LMNAKMT2AMEN1
SCHEMBL3324694 0.80 CA2 (0.66) CA2CA1
SCHEMBL8587216 0.79 NPC1 (0.57) RAB9ANPC1LMNAKMT2AMEN1
SCHEMBL865161 0.79 ALDH1A1 (0.39) RAB9ANPC1LMNAKMT2AMEN1
SCHEMBL5940593 0.78 NPC1 (0.55) RAB9ANPC1LMNAKMT2AMEN1
SCHEMBL2660297 0.76 CA2 (0.66) RAB9ANPC1LMNAKMT2AMEN1
SCHEMBL5925500 0.76 CA2 (0.66) RAB9ANPC1LMNAKMT2AMEN1
SCHEMBL12460109 0.75 RAB9A (0.65) RAB9ANPC1LMNAKMT2AMEN1
SCHEMBL14117645 0.75 ALDH1A1 (0.66) RAB9ANPC1LMNAKMT2AMEN1
SCHEMBL28021562 0.75 POLB (0.55) RAB9ANPC1LMNAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060235035-A1 Novel methoxybenzamibe compounds for use in mch receptor related disorders 7TM PHARMA A/S (DK) 2006-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235035-A1 Novel methoxybenzamibe compounds for use in mch receptor related disorders GPR119, MCHR2, HCRTR2 RAB9A 3657/4885NPC1 2225/4885LMNA 3546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.